Introduction
- PD1 Immune Checkpoint Inhibitors (ICIs) have been integrated into treatment algorithms for a variety of solid tumor malignancies, including head and neck squamous cell carcinoma (HNSCC)
- Durable response to single agent therapy occurs in only a fraction of patients.
- There is a great need to understand the molecular underpinnings of response and resistance mechanisms.
- PIK3CA mutation is a common driver of HPV+ mediated malignancy
- We sought to understand the prevalence and clinical impact of PIK3CA mutation in HPV+ and HPV- cancer by applying a multi-omics approach to a large, clinically appended dataset.